Enliven Therapeutics, Inc. Current ratio
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| Current ratio | 12.4x | 4.2x | 7.3x | 88.4x | 19.2x | 8.0x | 10.3x |
Enliven Therapeutics, Inc. (ELVN) Current ratio comparison analysis
General
LTM Current ratio
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
ELVN key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.6 | 0.3 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.0) 0.0% | (0.1) 0.0% | (0.1) 0.0% | (0.6) 0.0% | (0.3) 0.0% |
| Operating Expenses | 8.9 | 10.7 | 24.1 | 9.3 | 24.8 | 38.8 | 83.5 |
| Research & Development Expenses (R&D) | 7.9 | 8.2 | 19.0 | 8.2 | 20.5 | 31.0 | 64.6 |
| Selling, General & Administrative Expenses (SG&A) | 1.0 | 2.4 | 5.1 | 1.1 | 4.3 | 7.8 | 19.0 |
% margin | (8.9) 0.0% | (10.7) 0.0% | (24.1) 0.0% | (9.3) 0.0% | (24.8) 0.0% | (38.8) 0.0% | (83.5) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 1.1 | 12.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | 0.2 | (11.3) | (23.5) | (19.0) | (24.7) | (37.7) | (71.6) |
% effective tax rate | 0.2 100.0% | (0.8) 7.2% | 0.7 (2.8%) | (0.0) 0.2% | (0.0) 0.1% | 0.1 (0.2%) | 0.0 0.0% |
% margin | 0.0 0.0% | (11.3) 0.0% | (23.5) 0.0% | (18.9) 0.0% | (24.7) 0.0% | (37.8) 0.0% | (71.6) 0.0% |
| EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
| Diluted EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
% margin | 0.2 0.0% | (11.3) 0.0% | (23.4) 0.0% | (9.3) 0.0% | (24.6) 0.0% | (38.6) 0.0% | (81.9) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Enliven Therapeutics, Inc.'s Current ratio?
As of today, Microsoft Corp's last 12-month Current ratio is 17.4x, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Current ratio for Enliven Therapeutics, Inc. have been 19.0x over the past three years, and 18.5x over the past five years.
2) Is Enliven Therapeutics, Inc.'s Current ratio Good?
As of today, Enliven Therapeutics, Inc.'s Current ratio is 17.4x, which is higher than industry median of 4.6x. It indicates that Enliven Therapeutics, Inc.'s Current ratio is Good.